Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide

  title={Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide},
  author={Caroline Lagneux and Daniel Lamontagne},
  journal={British Journal of Pharmacology},
We have examined the involvement of the endocannabinoid system in the cardioprotection triggered by lipopolysaccharide (LPS). Rats were treated with saline or LPS (10 μg Kg−1). 24 h later, hearts were excised, retrogradely perfused, submitted to a low‐flow ischaemia (0.6 ml min−1) for 90 min and reperfused for 60 min. Some hearts were perfused with either SR 141716A (a cannabinoid CB1, receptor antagonist 1 μM), SR 144528 (a CB2 receptor anagonist μM), NNLA (3 μM) or sodium nitroprusside (1 μM… 

Signaling pathways involved in the cardioprotective effects of cannabinoids.

The selective CB(2)-receptor agonist JWH133 is able to reduce infarct size when administered either before ischemia, during the entire ischemic period, or just upon reperfusion, and data suggest that NO may contribute to the cardioprotective effect of some cannabinoids.

Endocannabinoids protect the rat isolated heart against ischaemia

Endocannabinoids exert a strong cardioprotective effect in a rat model of ischaemia–reperfusion that is mediated mainly through CB2‐receptors, and involves p38, ERK1/2, as well as PKC activation.

2-Arachidonylglycerol Acting on CB1 Cannabinoid Receptors Mediates Delayed Cardioprotection Induced by Nitric Oxide in Rat Isolated Hearts

It is concluded that delayed PC through transdermal nitroglycerin application increases the production of the endocannabinoid 2-AG which elicits protective effects against myocardial infarction via CB1 cannabinoid receptors which represents one new mechanism of NO-mediated PC.

E ndocannabinoids are implicated in the infarct size-reducing effect conferred by heat stress preconditioning in isolated rat hearts

The results suggest an involvement of endocannabinoids, acting through CB receptors, and NO in the cardioprotection conferred by heat stress 2 against myocardial ischaemia.

CB(2) cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion.

The cannabinoid CB1 receptor antagonist, rimonabant, protects against acute myocardial infarction

Rimonabant-induced infarct limitation may involve the CB1 receptor, although not necessarily cardiac CB1 receptors, and is unrelated to weight loss or altered adiponectin synthesis.



The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells.

Results indicate a functional linkage between the CB1 receptor and cannabinoid-mediated inhibition of NO production by rat microglial cells.

Inhibition of nitric oxide production in RAW264.7 macrophages by cannabinoids and palmitoylethanolamide.

Presynaptic cannabinoid and imidazoline receptors in the human heart and their potential relationship

In conclusion, inhibitory cannabinoid CB1 receptors are present on the sympathetic axon terminals of human atrial appendages and these receptors may have certain binding domains in common or that they interact with each other in an unknown manner.

Reperfusion injury in the endotoxin‐treated rat heart: reevaluation of the role of nitric oxide

LPS‐treated hearts demonstrate a basal decrease in FCC and coronary vascular resistance and Induction of NO synthesis, and possibly PGI2 release, may underlie cardioprotection from ischaemia‐reperfusion.

Cannabinoids cause central sympathoexcitation and bradycardia in rabbits.

The results indicate that cannabinoids, acting directly on cardiovascular regulatory centers, elicit sympathoactivation and bradycardia.

Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice.

Findings indicate a role for the CB1 receptor subtype in cytokine modulation by CB ligands in mice primed with Corynebacterium parvum and unprimed mice.

Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors.

Similar rank orders of potency, stereoselectivity and sensitivity to blockade by SR141716A indicate the involvement of CB1-like receptors in the hypotensive and bradycardic actions of cannabinoids, whereas the mechanism of the pressor effect of THC and anandamide remains unclear.

SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.

It is expected that SR 144528 will provide a powerful tool to investigate the in vivo functions of the cannabinoid system in the immune response.

Platelet‐ and macrophage‐derived endogenous cannabinoids are involved in endotoxin‐induced hypotension

It is demonstrated that rat platelets contain the endogenous cannabinoid 2‐arachidonyl glyceride (2‐AG), as identified by reverse phase high‐performance liquid Chromatography, gas chromatography, and mass spectrometry, and that in vitro exposure of platelets to LPS markedly increases 2‐AG levels.